UK markets closed

NVO Jan 2025 140.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
13.86-0.84 (-5.71%)
As of 12:17PM EDT. Market open.
Full screen
Previous close14.70
Open13.86
Bid14.10
Ask14.50
Strike140.00
Expiry date2025-01-17
Day's range13.86 - 13.86
Contract rangeN/A
Volume1
Open interest287
  • Benzinga

    Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns

    Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Eli Lilly And Co’s (NYSE:LLY) Mounjaro, citing safety concerns. Recently, the Chinese regulatory authority approved Eli Lilly’s diabetes drug, tirzepatide. Health Minister Mark Butler emphasized that these unregulated copies have not undergone rigorous testing, leading to potential patient risks. Related: The Ozempic Diet: Nestle Launches $5 Pizza For Weight

  • Zacks

    Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar

    Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).

  • Zacks

    Play These New ETFs to Tap Lucrative Weight Loss Drug Market

    Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.